newsfilter
← Latest News
Business Wire·

Adagio Medical to Participate in the TD Cowen 46th Annual Healthcare Conference

  • Adagio Medical Holdings will present at the TD Cowen 46th Annual Healthcare Conference on March 3, 2026, at 2:30 PM ET in Boston.
  • A live webcast & replay of the presentation will be available at event.summitcast.com or investors.adagiomedical.com.
  • The company utilizes proprietary Ultra-Low Temperature Cardiac (ULTA) ablation technology to create large, durable lesions in cardiac tissue.
  • Adagio is evaluating its vCLAS Cryoablation System in the FULCRUM-VT U.S. Pivotal IDE Trial for treating ventricular arrhythmias.
  • The FULCRUM-VT trial is a prospective, multi-center study that has fully enrolled 209 patients with structural heart disease & drug-refractory ventricular tachycardia.
  • Results from the trial will support an FDA premarket approval application for the vCLAS system to potentially establish the broadest indication for endocardial ablation of scar-mediated VT.
  • The vCLAS system holds CE Mark status & is commercially available in Europe & select geographies, but remains investigational in the United States.